An enhancer peptide for membrane-disrupting antimicrobial peptides by Ueno, Satoshi et al.
RESEARCH ARTICLE Open Access
An enhancer peptide for membrane-disrupting
antimicrobial peptides
Satoshi Ueno
1,2†, Kohtaro Kusaka
1†, Yasushi Tamada
1, Hong Zhang
1, Masaomi Minaba
1, Yusuke Kato
1*†
Abstract
Background: NP4P is a synthetic peptide derived from a natural, non-antimicrobial peptide fragment (pro-region
of nematode cecropin P4) by substitution of all acidic amino acid residues with amides (i.e., Glu ® Gln, and
Asp ® Asn).
Results: In the presence of NP4P, some membrane-disrupting antimicrobial peptides (ASABF-a, polymyxin B, and
nisin) killed microbes at lower concentration (e.g., 10 times lower minimum bactericidal concentration for ASABF-a
against Staphylococcus aureus), whereas NP4P itself was not bactericidal and did not interfere with bacterial growth
at ≤ 300 μg/mL. In contrast, the activities of antimicrobial agents with a distinct mode of action (indolicidin,
ampicillin, kanamycin, and enrofloxacin) were unaffected. Although the membrane-disrupting activity of NP4P was
slight or undetectable, ASABF-a permeabilized S. aureus membranes with enhanced efficacy in the presence of
NP4P.
Conclusions: NP4P selectively enhanced the bactericidal activities of membrane-disrupting antimicrobial peptides
by increasing the efficacy of membrane disruption against the cytoplasmic membrane.
Background
Antimicrobial peptides (AMPs) are peptides that are
selectively toxic against microbes. To date, more than
800 AMPs have been discovered in various organisms
including vertebrates, invertebrates, plants, protozoans,
and microbes. The structures of AMPs are extremely
diverse. They are categorized into distinct structural
groups such as amphipathic a-helical peptides, and b-
sheet peptides stabilized by intramolecular disulfide
bridges [1]. Several AMPs are already in practical use.
For instance, nisin is a widely used food-preservative in
more than 50 countries including the United States of
America, and countries within the European Union [2].
Polymyxin B has been used as a clinical antibiotic for
more than half a century [3]. Many AMPs have also
been investigated for practical use [4]. Microbial killing
by AMPs is often correlated mainly with membrane dis-
ruption although some other intracelluar and extracellu-
lar mechanisms also contribute to overall activity [1].
Several AMPs such as indolicidin attack intracellular
targets without membrane disruption [5].
Using combinations of agents is common in a clinical
setting in order to obtain more effective antimicrobial
properties. Such combinatorial application is also effec-
tive for AMPs. Conventional low-molecular-mass anti-
microbials often exhibit synergistic effects with AMPs
[6]. Synergy is also observed in some combinations of
AMPs naturally coexisting in the tissues of producing
organisms, e.g., magainin 2 and PGLa [7], different iso-
mers of dermaseptins and temporins [8,9], cathelicidins
and defensins [10], b-defensin and BPI [11], hepcidin
and moronecidin [12], Cg-Prp and Cg-Def [13], and
AFP and sarcotoxin IA [14]. Certain artificial combina-
tions of AMPs isolated from distinct organisms are
synergistic, e.g., some eukaryotic AMPs and bacteriocins
[15], and magainin and tachyplesin I [16]. Lysozymes,
1,4-b-N-acetylmurmidases with membrane-perturbing
activity, are synergistic with many AMPs [17,18]. The
staphylococcal glycylglycine endopeptidase lysostaphin is
also synergistic with polymyxin B and ranalexin [19,20].
All synergies mentioned above are found in combina-
tions of AMPs and other antimicrobials including
AMPs.
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ities by a synthetic peptide NP4P (Y. Kato, K. Kusaka, S.
Ueno, H. Zhang, and M. Minaba, 8 May 2008, Japanese
Patent Office). Increase in positive charge facilitates the
interaction of peptides with negatively charged biological
membranes, and often results in the conferring of mem-
brane-disrupting or membrane-penetrating activities.
We generated some peptides derived from natural non-
antimicrobial sequences, with modification to confer a
cationic net charge. These peptides were then subjected
to screening for novel AMPs that have structures dis-
tinct from those of known AMPs. NP4P was originally
one of these peptides. The parent peptide of NP4P was
a non-antimicrobial peptide fragment, nematode cecro-
pin P4 pro-region (P4P, calculated pI = 5.80) [21,22].
NP4P was generated from P4P by substitution of all
acidic amino acid residues with amides (i.e., Glu ® Gln,
and Asp ® Asn), resulting in a reduction of negative
charge and an acquisition of stronger net positive charge
(Figure 1). It consisted of 30 amino acid residues and
was highly basic (calculated pI = 12.30). When evaluat-
ing the pharmacological properties of NP4P, we found
that NP4P enhanced the activities of some AMPs
whereas no antimicrobial activity was detected for NP4P
alone, suggesting that the effect of NP4P was an
enhancement, but not a synergy as mentioned above.
This study is the first report on the unique features of
NP4P.
Results and Discussion
Evaluation of antimicrobial activity of NP4P
Antimicrobial activity was evaluated as the first step in
pharmacological characterization of NP4P. We did not
detect antimicrobial activity for NP4P at ≤ 300 μg/mL
in growth-inhibitory and microbicidal assay against
certain Gram-positive bacteria (Staphylococcus aureus
IFO12732, Bacillus subtilis IFO03134, and Micrococcus
luteus IFO 12708); Gram-negative bacteria (Pseudomo-
nas aeruginosa IFO3899, Salmonella typhimurium
IFO13245, Serratia marcescens IFO3736 and Escherichia
coli JM109); and yeast (Saccharomyces cerevisiae
MAFF113011), as well as against monkey Vero kidney
cells (data not shown). In addition, NP4P (300 μg/mL)
did not affect the growth curves of S. aureus IFO12732
(Figure 2A) and E. coli JM109 (Figure 2B). These results
indicate that NP4P was less toxic to microbes.
Enhancer activity for antimicrobial peptides
The parent peptide P4P inhibited the bactericidal activ-
ity of cecropin P4 and some other antimicrobial pep-
t i d e s( [ 2 2 ] ;S .U e n oa n dY .Kato, unpublished data),
encouraging us to test whether NP4P affected the activ-
ities of other antimicrobial agents. We examined the
effect of NP4P on the bactericidal activities of the
nematode CSab- t y p ec a t i o n i cA M PA S A B F - a [23-25]
against S. aureus IFO12732 (Figure 3A) and polymyxin
Ba g a i n s tE. coli JM109 in 10 mM Tris-HCl, pH 7.4
(Figure 3B). Unexpectedly, NP4P enhanced these activ-
ities at ≥ 5 μg/mL in a dose-dependent manner. The
dose-effect curves of ASABF-a and polymyxin B were
shifted to almost 10 times lower concentration in the
presence of 100 μg/mL NP4P. However, the enhance-
ment was completely abolished in a high ionic strength
condition (150 mM NaCl, 50 mM NaHCO3,1 0m M
Tris-HCl, pH 7.4).
Furthermore, we tested NP4P enhancement at 20 μg/
mL for the activities of antimicrobial agents against var-
ious microbes (Table 1). The results can be summarized
as: (1) The bactericidal activities of all tested mem-
brane-disrupting AMPs (ASABF-a, polymyxin B, and
Figure 1 Structure of NP4P. The parent peptide, nematode cecropin P4 pro-piece (P4P), is shown at the top. Inversed letters indicate acidic
amino acid residues which were substituted with amides in NP4P. Letters on a grey background represent basic amino acid residues.
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tive depending on the type of bacterial species. For
instance, the activities of ASABF-a against S. aureus
IFO12732 and E. coli JM109 were enhanced, whereas a
lesser enhancement was observed against M. luteus IFO
12708, B. subtilis IFO3134, P. aeruginosa IFO3899, and
S. marcescens IFO3736. (3) NP4P did not enhance the
activity of one AMP indolicidin which killed bacteria by
inhibition of DNA synthesis and not by membrane dis-
ruption [5]. (4) NP4P did not affect the activities of
conventional antimicrobial agents that do not target
bacterial cytoplasmic membranes (ampicillin, kanamycin,
and enrofloxacin).
Effect on disruption of the cytoplasmic membrane
NP4P enhancement was observed only for the antimi-
crobial activities of membrane-disrupting AMPs. The
simplest hypothesis accounting for NP4P enhancement
was direct facilitation of membrane disruption. To test
this hypothesis, we examined the effect of NP4P on the
Figure 2 Effect of NP4P on bacterial growth. Staphylococcus aureus IFO12732 (A) and Escherichia coli JM109 (B) in the logarithmic phase were
suspended in 2 mL of IFO702 medium with or without 300 μg/mL of NP4P. Their optical densities were adjusted to 0.06-0.08 at 600 nm. The
bacterial suspension was incubated at 30°C. Bacterial growth was estimated by measuring the change in optical density. All experiments were
performed in triplicate. Each data point represents the mean ± SEM.
Figure 3 NP4P enhancement of bactericidal activities of AMPs. The dose-effect curves were determined in the presence of NP4P at various
concentrations (0, 2.5, 5, 20, and 100 μg/mL). Bactericidal activities were measured against S. aureus IFO12732 for ASABF-a (A) and against E. coli
JM109 to polymyxin B (B). Viability is defined as normalized number of viable cells to the number in the absence of ASABF-a or polymyxin B.
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diS-C3-(5) is a slow-response voltage-sensitive fluores-
cent dye [26]. The extracellularly administered diS-C3-
(5) accumulates on the hyperpolarized cell membrane,
translocates into the lipid bilayer, and redistributes
between the cells and the medium in accordance with
the membrane potential. Aggregation within the con-
fined membrane interior or intracellular spaces usually
results in reduced fluorescence by self-quenching. Depo-
larization or disruption of the cytoplasmic membrane
causes the release of diS-C3-(5) from the cells to the
medium and an increase in fluorescence intensity.
ASABF-a evoked the increase in fluorescence against
diS-C3-(5)-loaded S. aureus IFO12732 in a dose-depen-
dent manner (Figure 4A). ASABF-a induced calcein
(molar mass = 622.53) leakage from the acidic-lipo-
somes (data not shown), indicating that the increase in
fluorescence was attributed to leakage of diS-C3-(5) by
membrane disruption rather than redistribution by
depolarization. Bactercidal activity was parallel to the
release of diS-C3-(5) (Figure 4B), suggesting that
ASABF-a killed S. aureus mainly by disruption of the
cytoplasmic membrane.
The effect of NP4P was investigated using this experi-
mental setting. NP4P evoked no significant change in
fluorescence at ≤ 10 μg/mL whereas weak ripples or
limited increase were observed at higher concentrations
(2.5% of maximal response at 100 μg/mL: the maximal
response was defined as the increase in fluorescence at
the plateau in the dose-response curve of ASABF-a)
(Figure 4C). In addition, NP4P did not disrupt the
acidic-liposomal membrane at ≤ 220 μg/mL (data not
shown). This suggests that NP4P barely affected either
the membrane permeability or membrane potential of S.
aureus. To test the effect of NP4P on the membrane-
disrupting activity of ASABF-a, dose-response curves
were determined in the presence or absence of NP4P
(Figure 4D). The efficacy of membrane disruption by
ASABF-a was remarkably enhanced by NP4P in a dose-
dependent manner. The threshold concentration of
ASABF-a was not significantly affected. Several doses of
NP4P were added to S. aureus which was intermediately
damaged by 1.28 μg/mL of ASABF-a [36% increase in
maximal response in diS-C3-(5) fluorescence] (Figure
4E). Even 1 μg/mL of NP4P caused detectable enhance-
ment. The degree of enhancement increased dose-
dependently. These results suggest that NP4P enhances
the bactericidal activity of ASABF-a by increasing the
efficacy of membrane disruption.
AMPs from the skin of a frog, PGLa and magainin 2,
form heterodimers and show synergistic membrane dis-
ruption and antimicrobial activities [7,27]. NP4P is not
as likely to bind directly with AMPs as PGLa and
magainin 2 because the structure of ASABF-a,n i s i n ,
and polymyxin B, whose bactericidal activities were
enhanced by NP4P, are completely distinct [28-30].
NP4P is a highly basic molecule and could interact with
negatively charged cytoplasmic membranes. A possible
mechanism of NP4P enhancement is destabilization of
the cytoplasmic membrane. Whereas NP4P did not
exhibit neither growth inhibitory nor bactericidal activity
against S. aureus at ≤ 200 μg/ml, ripples or weak
increase in diS-C3-(5) fluorescence was evoked at > 10
μg/mL, suggesting that NP4P interacted with bacterial
cytoplasmic membranes and caused sublethal membrane
destabilization. For acidic liposomes, NP4P neither
evoked such membrane destabilization-like responses
nor enhanced membrane disruption of ASABF-a.H o w -
ever, the results obtained by quantifying bacterial mem-
brane disruption using using diS-C3-(5) may indicate the
more specific mode of action. The intensities of
enhancement did not correlate with the susceptibilities
of the bacteria for the tested AMPs. The killing of E.
coli JM109 was most efficiently enhanced for ASABF-a
and polymyxin B, suggesting that the efficacy of NP4P
Table 1 Effect on MBC values of various antimicrobial
agents
MBC (μg/mL)
NP4P-
a NP4P+
ASABF-a
b
Staphylococcus aureus IFO12732 3 0.3
Micrococcus luteus IFO12708 5 2
Bacillus subtilis IFO3134 8 3
Escherichia coli JM109 3 0.3
Pseudomonas aeruginosa IFO3899 5 2
Salmonella typhimurium IFO13245 3 2
Serratia marcescens IFO3736 3 1.5
Polymyxin B
b
Escherichia coli JM109 3 0.3
Pseudomonas aeruginosa IFO3899 5 2.5
Salmonella typhimurium IFO13245 5 2.5
Serratia marcescens IFO3736 5 1
Nisin
b
Staphylococcus aureus IFO12732 5 2
Indolicidin
c
Staphylococcus aureus IFO12732 10 10
Escherichia coli JM109 10 10
Ampicillin
c
Staphylococcus aureus IFO12732 250 250
Kanamycin
c
Staphylococcus aureus IFO12732 3 3
Enrofloxacin
c
Staphylococcus aureus IFO12732 0.25 0.25
a Each MBC value was determined in the presence or absence of 20 μg/mL
NP4P.
b Membrane disruptive.
c Not membrane disruptive.
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than on that of AMPs. These results support our
hypothesis that NP4P independently interacts with cyto-
plasmic membranes and not with AMPs. For acidic lipo-
somes, membrane disruption of ASABF-a was inhibited
i nt h ep r e s e n c eo f2 0μg/mL NP4P. The dose-response
curve was shifted to a higher concentration (IC50 =0 . 2 3
μg/mL without NP4P, and 0.53 μg/ml with NP4P), indi-
cating that NP4P was a competitive inhibitor. This inhi-
bition could be due to charge neutralization of the
membrane surface by NP4P binding and prevention of
ASABF-a binding in a similar manner to that observed
between magainin 2 and an acyclic tachyplesin I analo-
gue [16], i.e., NP4P and ASABF-a also bind to the lipo-
somal membrane independently. This observation does
not contradict our hypothesis mentioned above. The
exact mechanisms for NP4P enhancement at the mole-
cular level remains to be elucidated.
Conclusions
NP4P selectively enhances the bactericidal activities of
membrane-disrupting AMPs (ASABF-a, nisin, and poly-
myxin B). NP4P is not bactericidal and does not inhibit
growth at ≤ 300 μg/mL against all tested bacteria, sug-
gesting that the effect of NP4P is enhancement and is
distinct from the previously reported synergy among
AMPs and/or low-molecular mass antimicrobials [6-20].
Enhancement intensities depend on microbial species.
Relatively good enhancement was achieved for S. aureus
and E. coli. Increasing the efficacy of membrane disrup-
tion against the bacterial cytoplasmic membrane may
contribute to enhancement by NP4P.
AMPs are immune effectors against microbial infec-
tions in vertebrates, invertebrates, and plants. In
humans, the deficiency in AMP functions often causes
reduced resistance against infectious diseases [31,32],
indicating that resistance may increase by enhancing the
effect of AMPs. AMP-enhancers without antimicrobial
activities are promising as immunopotentiators since
they do not disturb the autonomic control of immunity.
Although salt-inhibition remains to be resolved for prac-
tical use in mammals, NP4P is believed to be the first
peptide which exerts AMP-enhancer activity.
Methods
Microorganisms
E. coli JM109 was purchased from Takara (Otsu, Japan).
Other strains described below were transferred from the
National Institute of Technology and Evaluation,
Kazusa, Japan: S. aureus IFO12732, B. subtilis IFO3134,
M. luteus IFO12708, P. aeruginosa IFO3899, S. typhi-
murium IFO13245 and S. marcescens IFO3736.
Peptides and other AMPs
NP4P, cecropin P4 and indolicidin were prepared at
Biologica Co. (Nagoya, Japan). Briefly, peptides were
Figure 4 Effect of NP4P on the membrane-disrupting activity of ASABF-a against the cytoplasmic membrane of S. aureus. Disruption of
the cytoplasmic membrane was estimated by the increase in fluorescence intensity of diS-C3-(5). Changes in fluorescence were normalized by
the value at the plateau of the dose-response curves. (A) Dose-response curve and (B) dose-bactericidal effect curve of ASABF-a against S. aureus
IFO12732. These curves were simultaneously determined. The asterisks indicate that viable cells were not detected. (C) Effect of NP4P on the
cytoplasmic membrane. The time courses of fluorescence changes are represented. (D) Effect of NP4P on cytoplasmic membrane disruption by
ASABF-a. Dose-response curves were determined in the presence of NP4P at various concentrations (0, 30, and 100 μg/ml). (E) Another assay for
NP4P enhancement. NP4P was applied after treatment of 1.28 μg/mL of ASABF-a. The fluorescent change evoked only by ASABF-a is indicated
by a dashed line.
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reversed-phase high-pressure liquid chromatography.
The products were confirmed by time-of-flight mass
spectrometry on a Voyager DE Mass Spectrometer,
Applied Biosystems (Foster City, CA, USA). ASABF-a
was prepared as previously described [24]. Some antimi-
crobials were purchased from Wako, Osaka, Japan
(ampicillin, kanamycin, and polymyxin B); Sigma, St.
Louis, MO, USA (nisin); and Bayer, Nordrhein-Westfa-
len, Germany (enrofloxacin).
Growth assay
Microbes in the mid-exponential phase were suspended
in 2 mL of IFO702 medium (1% polypeptone, 0.2% yeast
extract, 0.1% MgSO4/7H2O) with or without NP4P.
Their optical densities were adjusted to an OD600 of
0.06-0.08. The bacterial suspension was incubated at
30°C. Bacterial growth was estimated by measuring
the change in OD600.
Monkey Vero cells were grown in 2 ml of Dulbecco’s
modified Eagle’s medium supplemented with 5% fetal
bovine serum at 37°C and 5% CO2. To estimate cyto-
toxicity, NP4P was added to the medium at 0, 30, 100,
and 300 μg/mL. Cell proliferation and morphorogy were
monitored for a week.
Microbicidal assay
Microbicidal assay was performed as previously
described [33]. Briefly, each microbial strain in the mid-
exponential phase was suspended in 10 mM Tris/HCl,
pH 7.5. The microbial suspension was mixed with anti-
microbials in the presence or absense of NP4P. After
2 h incubation, the suspension was diluted 1,000 times
and inoculated on to plates of IFO702 medium. The
number of colonies were counted, and a plot of peptide
concentration vs colony number was created.
Liposome disruption assay
Membrane-disrupting activity was estimated by lipo-
some disruption assay [33]. A lipid film was prepared by
rotary evaporation of lipid solution [1 mg lipid in 1 mL
chloroform, phosphatidylglycerol (mole):caldiolipin
(mole) = 3:1]. The lipid film was hydrated with 1 mL of
10 mM Tris-HCl buffer (pH 7.5) containing 75 mM cal-
cein. Lipid dispersions were sonicated and subjected to
five freeze-thaw cycles. Non-trapped calcein was
removed by gel filtration on a Sephacryl S-300 spin col-
umn (GE Healthcare Bio-Science Corp., Piscataway, NJ,
USA) equilibrated with 10 mM Tris-HCl (pH 7.5) con-
taining 175 mM NaCl and 1 mM EDTA. These calcein-
entrapped liposomes were diluted at a ratio of 1:1000 in
10 mM Tris-HCl (pH 7.5) containing 350 mM sucrose.
Calcein release after membrane disruption was evaluated
by measuring fluorescence intensity at 515 nm with
excitation at 492 nm on a Shimadzu RF-5300PC spec-
trofluorometer (Shimadzu, Kyoto, Japan) at room
temperature.
Cytoplasmic membrane permeability assay
Cytoplasmic membrane permeabilization of S. aureus
was determined with a voltage-sensitive dye, diS-C3-(5)
[34,35]. Bacteria in the mid-exponential phase were sus-
pended in 10 mM Tris-HCl with or without NP4P, pH
7.5 to an OD600 of 0.05. Changes in fluorescence were
continuously monitored using a Shimadzu RF-5300PC
spectrofluorometer at an excitation wavelength of
622 nm and an emission wavelength of 670 nm. The
bacterial suspension was incubated with 400 nM diS-C3-
(5). ASABF-a was added to the bacterial suspension
after the dye uptake was maximal. The maximal increase
in fluorescence due to disruption of the cytoplasmic
membrane was recorded.
Acknowledgements
This work was partly supported by research fellowships of the Japan Society
for the Promotion of Science for Young Scientists (to SU).
Author details
1Division of Insect Sciences, National Institute of Agrobiological Sciences,
Oowashi 1-2, Tsukuba, Ibaraki 305-8634, Japan.
2Graduate School of Life and
Environmental Sciences, University of Tsukuba, Tennoudai 1-1-1, Tsukuba,
Ibaraki 305-8572, Japan.
Authors’ contributions
SU, KK, and YK designed and performed most of the experimental work. SU
and YT performed the experiment using liposomes. MM and HZ has mainly
performed the antimicrobial assay. YK edited the manuscript. This study
conducted completely under the supervision of YK. All authors read and
approved the final manuscript.
Received: 30 June 2009
Accepted: 15 February 2010 Published: 15 February 2010
References
1. Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors
in bacteria?. Nat Rev Microbiol 2005, 3:238-250.
2. 21 CFR Ch.I (4-1-03 Edition) Food and Drug Administration,
HHS.§184.1538. 2003.
3. Landman D, Georgescu C, Martin DA, Quale J: Polymyxins revisited. Clin
Microbiol Rev 2008, 21:449-465.
4. Hancock REW, Sahl HG: Antimicrobial and host-defense peptides as
new anti-infective therapeutic strategies. Nat Biotechnol 2006,
24:1151-1157.
5. Subbalakshimi C, Sitaram N: Mechanism of antimicrobial action of
indolicidin. FEMS Microbiol Lett 1998, 160:91-96.
6. Giacometti A, Cirioni O, Riva A, Kamysz W, Silvestri C, Nadolski P, Della
Vittoria A, Łkasiak J, Scalise G: In vitro activity of aurein 1.2 alone and in
combination with antibiotics against gram-positive nosocomial cocci.
Antimicrob Agents Chemother 2007, 51:1494-1496.
7. Westerhoff HV, Zasloff M, Rosner JL, Hendler W, De Waal A, Vaz Gomes A,
Jongsma PM, Riethorst A, Juretić D: Functional synergism of the
magainins PGLa and magainin-2 in Escherichia coli, tumor cells and
liposomes. Eur J Biochem 1995, 228:257-264.
8. Mor A, Hani K, Nicolas P: The vertebrate peptide antibiotics dermaseptins
have overlapping structural features but target specific microorganisms.
J Biol Chem 1994, 269:31635-31641.
9. Rosenfeld Y, Barra D, Simmaco M, Shai Y, Mangoni ML: A synergism
between temporins toward Gram-negative bacteria overcomes
Ueno et al. BMC Microbiology 2010, 10:46
http://www.biomedcentral.com/1471-2180/10/46
Page 6 of 7resistance imposed by the lipopolysaccharide protective layer. J Biol
Chem 2006, 281:28565-28574.
10. Nagaoka I, Hirota S, Yomogida S, Ohwada A, Hirata M: Synergistic actions
of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 2000,
49:73-79.
11. Levy O, Ooi CE, Weiss J, Lehrer RL, Elsbach P: Individual and synergistic
effects of rabbit granulocyte proteins on Escherichia coli. J Clin Investig
1994, 94:672-682.
12. Lauth X, Babon JJ, Stannard JA, Singh S, Nizet V, Carlberg JM, Ostland VE,
Pennington MW, Norton RS, Westerman ME: Bass hepcidin synthesis,
solution structure, antimicrobial activities and synergism, and in vivo
hepatic response to bacterial infections. J Biol Chem 2005, 280:9272-9282.
13. Gueguen Y, Romestand B, Fievet J, Schmitt P, Destoumieux-Garzón D,
Vandenbulcke F, Bulet P, Bachère E: Oyster hemocytes express a proline-
rich peptide displaying synergistic antimicrobial activity with a defensin.
Mol Immunol 2009, 46:516-522.
14. Iijima R, Kurata S, Natori S: Purification, characterization, and cDNA
cloning of an antifungal protein from the hemolymph of Sarcophaga
peregrina (flesh fly) larvae. J Biol Chem 1993, 268:12055-12061.
15. Lüders T, Birkemo GA, Fimland G, Nissen-Meyer J, Nes IF: Strong synergy
between a eukaryotic antimicrobial peptide and bacteriocins from lactic
acid bacteria. Appl Environ Microbiol 2003, 69:1797-1799.
16. Kobayashi S, Hirakura Y, Matsuzaki K: Bacteria-selective synergism between
the antimicrobial peptides alpha-helical magainin 2 and cyclic beta-
sheet tachyplesin I: toward cocktail therapy. Biochemistry 2001,
40:14330-14335.
17. Chalk R, Albuquerque CM, Ham PJ, Townson H: Full sequence and
characterization of two insect defensins: immune peptides from the
mosquito Aedes aegypti. Proc Biol Sci 1995, 261:217-221.
18. Yan H, Hancock REW: Synergistic interactions between mammalian
antimicrobial defense peptides. Antimicrob Agents Chemother 2001,
45:1558-1560.
19. Polak J, Della Latta P, Blackburn P: In vitro activity of recombinant
lysostaphin-antibiotic combinations toward methicillin-resistant
Staphylococcus aureus. Diagn Microbiol Infect Dis 1993, 17:265-270.
20. Graham S, Coote PJ: Potent, synergistic inhibition of Staphylococcus
aureus upon exposure to a combination of the endopeptidase
lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother
2007, 59:759-762.
21. Pillai A, Ueno S, Zhang H, Lee JM, Kato Y: Cecropin P1 and novel
nematode cecropins: a bacteria-inducible antimicrobial peptide family in
the nematode Ascaris suum. Biochem J 2005, 390:207-214.
22. Ueno S, Kusaka K, Tamada Y, Minaba M, Zhang H, Wang PC, Kato Y:
Anionic C-terminal proregion of nematode antimicrobial peptide
cecropin P4 precursor inhibits antimicrobial activity of the mature
peptide. Biosci Biotechnol Biochem 2008, 72:3281-3284.
23. Kato Y, Komatsu S: ASABF, a novel cysteine-rich antibacterial peptide
isolated from the nematode Ascaris suum: purification, primary structure,
and molecular cloning of cDNA. J Biol Chem 1996, 271:30493-30498.
24. Zhang H, Yoshida S, Aizawa T, Murakami R, Suzuki M, Koganezawa N,
Masuura A, Miyazawa M, Kawano K, Nitta K, Kato Y: In vitro antimicrobial
properties of recombinant ASABF, an antimicrobial peptide isolated
from the nematode Ascaris suum. Antimicrob Agents Chemother 2000,
44:2701-2705.
25. Pillai A, Ueno S, Zhang H, Kato Y: Induction of ASABF (Ascaris suum
antibacterial factor)-type antimicrobial peptides by bacterial injection:
novel members of ASABF in the nematode Ascaris suum. Biochem J 2003,
371:663-668.
26. Sims PJ, Waggoner AS, Wang CH, Hoffman JF: Studies on the mechanism
by which cyanine dyes measure membrane potential in red blood cells
and phosphatidylcholine vesicles. Biochemistry 1974, 13:3315-3329.
27. Matsuzaki K, Mitani Y, Akada KY, Murase O, Yoneyama S, Zasloff M,
Miyajima K: Mechanism of synergism between antimicrobial peptides
magainin 2 and PGLa. Biochemistry 1998, 37:15144-15153.
28. Aizawa T, Hoshino H, Fujitani N, Koganesawa N, Matsuura A, Miyazawa M,
Kato Y, Kumaki Y, Demura M, Nitta K, Kawano K: Structural analysis of an
antibacterial peptide derived from a nematode. Peptide Science 2000 The
Japanese Peptide SocietyShioiri T 2001, 269-272.
29. Van den Hooven HW, Doeland CC, Van De Kamp M, Konings RN,
Hilbers CW, Van De Ven FJ: Three-dimensional structure of the lantibiotic
nisin in the presence of membrane-mimetic micelles of
dodecylphosphocholine and of sodium dodecylsulphate. Eur J Biochem
1996, 235:394-403.
30. Chapman TM, Golden MR: Polymyxin B. NMR evidence for a peptide
antibiotic with folded structure in water. Biochem Biophys Res Commun
1972, 46:2040-2047.
31. Smith JJ, Travis SM, Greenberg EP, Welsh MJ: Cystic fibrosis airway
epithelia fail to kill bacteria because of abnormal airway surface fluid.
Cell 1996, 85:229-236.
32. Pütsep K, Carlsson G, Boman HG, Andersson M: Deficiency of antibacterial
peptides in patients with morbus Kostmann: an observation study.
Lancet 2002, 360:1144-1149.
33. Zhang H, Morikawa K, Ohta T, Kato Y: In vitro resistance to the CSab-type
antimicrobial peptide ASABF-a is conferred by overexpression of sigma
factor sigB in Staphylococcus aureus. J Antimicrob Chemother 2005,
55:686-691.
34. Weinstein JN, Yoshikami S, Henkart P, Blumenthal R, Hagins WA: Liposome-
cell interaction: transfer and intracellular release of a trapped
fluorescent marker. Science 1977, 195:489-491.
35. Friedrich CL, Moyles D, Beveridge TJ, Hancock REW: Antibacterial action of
structurally diverse cationic peptides on Gram-positive bacteria.
Antimicrob Agents Chemother 2000, 44:2086-2092.
doi:10.1186/1471-2180-10-46
Cite this article as: Ueno et al.: An enhancer peptide for membrane-
disrupting antimicrobial peptides. BMC Microbiology 2010 10:46.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ueno et al. BMC Microbiology 2010, 10:46
http://www.biomedcentral.com/1471-2180/10/46
Page 7 of 7